View Item 

Show simple item record

Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents

dc.contributor.authorWalter, C. P.en_US
dc.contributor.authorBleske, B. E.en_US
dc.contributor.authorDorsch, M. P.en_US
dc.date.accessioned2014-09-03T16:51:35Z
dc.date.availableWITHHELD_14_MONTHSen_US
dc.date.available2014-09-03T16:51:35Z
dc.date.issued2014-10en_US
dc.identifier.citationWalter, C. P.; Bleske, B. E.; Dorsch, M. P. (2014). "Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents." Journal of Clinical Pharmacy and Therapeutics 39(5): 475-484.en_US
dc.identifier.issn0269-4727en_US
dc.identifier.issn1365-2710en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108287
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLorcaserinen_US
dc.subject.otherObesityen_US
dc.subject.otherPhentermine/Topiramateen_US
dc.subject.otherWeight Lossen_US
dc.titlePharmacotherapy for weight loss: the cardiovascular effects of the old and new agentsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108287/1/jcpt12177.pdf
dc.identifier.doi10.1111/jcpt.12177en_US
dc.identifier.sourceJournal of Clinical Pharmacy and Therapeuticsen_US
dc.identifier.citedreferenceProduct information. (BELVIQ) Lorcaserin. Zofingen, Switzerland: 2012.en_US
dc.identifier.citedreferencePasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience, 1999; 92: 601 – 611.en_US
dc.identifier.citedreferenceHuang X, Setola V, Yadav P. Parallel functional activity profiling reveals valvulopathogens are potent 5‐hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol Pharmacol, 2009; 76: 710 – 722. doi: 10.1124/mol.109.058057.en_US
dc.identifier.citedreferenceSmith SR, Weissman NJ, Anderson CM et al. Multicenter, placebo‐controlled trial of lorcaserin for weight management. N Engl J Med, 2010; 363: 245 – 256. doi: 10.1056/NEJMoa0909809.en_US
dc.identifier.citedreferenceFidler MC, Sanchez M, Raether B et al. A one‐year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab, 2011; 96: 3067 – 3077. doi: 10.1210/jc.2011‐1256.en_US
dc.identifier.citedreferenceO'Neil PM, Smith SR, Weissman NJ et al. Randomized placebo‐controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM‐DM study. Obesity (Silver Spring), 2012; 20: 1426 – 1436. doi: 10.1038/oby.2012.66.en_US
dc.identifier.citedreferenceFDA Briefing Document: NDA 22529. BELVIQ (lorcaserin). Arena Pharmaceuticals.en_US
dc.identifier.citedreferenceJaffré F, Bonnin P, Callebert J et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic‐dependent cardiac hypertrophy. Circ Res, 2009; 104: 113 – 123. doi: 10.1161/CIRCRESAHA.108.180976.en_US
dc.identifier.citedreferenceGadde KM, Allison DB, Ryan DH et al. Effects of low‐dose, controlled‐release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo‐controlled, phase 3 trial. Lancet, 2011; 377: 1341 – 1352. doi: 10.1016/S0140‐6736(11)60205‐5.en_US
dc.identifier.citedreferenceAllison DB, Gadde KM, Garvey WT et al. Controlled‐release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring), 2012; 20: 330 – 342. doi: 10.1038/oby.2011.330.en_US
dc.identifier.citedreferenceRichard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition, 2000; 16: 961 – 966.en_US
dc.identifier.citedreferenceRichard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord, 2002; 26: 344 – 353. doi: 10.1038/sj.ijo.0801873.en_US
dc.identifier.citedreferencePicard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res, 2000; 8: 656 – 663. doi: 10.1038/oby.2000.84.en_US
dc.identifier.citedreferenceFDA Briefing Document: NDA 022580. Qnexa (phentermine/topiramate). Vivus, Inc.en_US
dc.identifier.citedreferenceGarvey W, Ryan D, Look M. metabolic benefits with controlled‐release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo‐controlled, phase 3 extension. Am J Clin Nutr, 2012; 95: 297 – 308. doi: 10.3945/ajcn.111.024927.INTRODUCTION.en_US
dc.identifier.citedreferenceGreenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR‐I): a multicentre, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet, 2010; 376: 595 – 605. doi: 10.1016/S0140‐6736(10)60888‐4.en_US
dc.identifier.citedreferenceClinicalTrials.gov: A service of the U.S. National Institutes of Health. Available at: http://www.clinicaltrials.gov/. (accessed April 2013)en_US
dc.identifier.citedreferenceFlint A, Raben A, Astrup A, Holst J. Glucagon‐like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest, 1998; 101: 515 – 520.en_US
dc.identifier.citedreferenceNaslund E, King N, Mansten S et al. Prandial subcutaneous injections of glucagon‐like peptide‐1 cause weight loss in obese human subjects. Br J Nutr, 2004; 91: 439 – 446.en_US
dc.identifier.citedreferenceAngeli F, Shannon R. Incretin‐based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol, 2014; 221: T17 – T30.en_US
dc.identifier.citedreferenceFlegal K, Carroll M. Prevalence and trends in obesity among US adults, 1999–2000. JAMA, 2002; 288: 1723 – 1727.en_US
dc.identifier.citedreferenceOgden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief, 2012; 82: 1 – 8.en_US
dc.identifier.citedreferenceDouketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med, 2005; 5: 25 – 33. doi: 10.1055/s‐2005‐871739.en_US
dc.identifier.citedreferenceBillington C, Epstein L, Goodwin N et al. Overweight, obesity, and health risk. Arch Intern Med, 2000; 160: 898 – 904.en_US
dc.identifier.citedreferenceWing R, Lang W, Wadden T. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with Type 2 diabetes. Diabetes Care, 2011; 34: 1481 – 1486. doi: 10.2337/dc10‐2415.en_US
dc.identifier.citedreferenceBlack E, Holst C, Astrup A et al. Long‐term influences of body‐weight changes, independent of the attained weight, on risk of impaired glucose tolerance and Type 2 diabetes. Diabet Med, 2005; 22: 1199 – 1205. doi: 10.1111/j.1464‐5491.2005.01615.x.en_US
dc.identifier.citedreferenceGoldstein D. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord, 1992; 16: 397 – 415.en_US
dc.identifier.citedreferenceJensen MD, Ryan DH, Apovian CM et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 2013. doi: 10.1161/01.cir.0000437739.71477.ee [Epub ahead of print].en_US
dc.identifier.citedreferenceIoannides‐Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs, 2005; 65: 1391 – 1418.en_US
dc.identifier.citedreferenceNIH Publication. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.; 1998. Available at: http://hp2010.nhlbihin.net/oei_ss/download/pdf/CORESET1.pdf. (accessed 2 May 2013).en_US
dc.identifier.citedreferenceBray G. A concise review on the therapeutics of obesity. Nutrition, 2000; 16: 953 – 960.en_US
dc.identifier.citedreferenceWeintraub M, Hasday J. A double‐blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med, 1984; 144: 1143 – 1148.en_US
dc.identifier.citedreferenceGuy‐Grand B, Crepaldi G, Vre P International trial of long‐term dexfenfluramine in obesity. Lancet, 1989; 2: 1142 – 1145.en_US
dc.identifier.citedreferenceConnolly H, Crary J, McGoon M et al. Valvular heart disease associated with fenfluramine‐phentermine. N Engl J Med, 1997; 337: 581 – 588.en_US
dc.identifier.citedreferenceWee C, Phillips R, Aurigemma G et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med, 1998; 129: 870 – 874.en_US
dc.identifier.citedreferenceSachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine‐derivative diet pills on cardiac valves: a meta‐analysis of observational studies. Am Heart J, 2002; 144: 1065 – 1073. doi: 10.1067/mhj.2002.126733.en_US
dc.identifier.citedreferenceAbenhaim L, Moride Y, Brenot F et al. Appetite‐suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med, 1996; 335: 609 – 616. doi: 10.1381/096089297765556114.en_US
dc.identifier.citedreferenceRich S, Rubin L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest, 2000; 117: 870 – 874.en_US
dc.identifier.citedreferenceRothman RB, Baumann MH, Savage JE et al. Evidence for possible involvement of 5‐HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 2000; 102: 2836 – 2841.en_US
dc.identifier.citedreferenceRothman R, Baumann M. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf, 2009; 8: 317 – 329. doi: 10.1517/14740330902931524.Serotonergic.en_US
dc.identifier.citedreferenceFitzgerald LW, Burn TC, Brown BS et al. Possible role of valvular serotonin 5‐HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol, 2000; 57: 75 – 81.en_US
dc.identifier.citedreferenceEddahibi S, Adnot S. Anorexigen‐induced pulmonary hypertension and the serotonin (5‐HT) hypothesis: lessons for the future in pathogenesis. Respir Res, 2002; 3: 1 – 4.en_US
dc.identifier.citedreferenceDempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol, 2008; 155: 455 – 462. doi: 10.1038/bjp.2008.241.en_US
dc.identifier.citedreferenceScheen A. Cardiovascular risk‐benefit profile of sibutramine. Am J Cardiovasc Drugs, 2010; 10: 321 – 334.en_US
dc.identifier.citedreferenceProduct information. Meridia (sibutramine). Abbott Laboratories. 2001.en_US
dc.identifier.citedreferenceJames W, Caterson I. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med, 2010; 363: 905 – 917.en_US
dc.identifier.citedreferenceHaller CA, Jacob P, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single‐dose dietary supplement use. Clin Pharmacol Ther. 2002; 71: 421 – 432. doi: 10.1067/mcp.2002.124523.en_US
dc.identifier.citedreferenceHaller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med, 2000; 343: 1833 – 1838. doi: 10.1056/NEJM200012213432502.en_US
dc.identifier.citedreferenceShekelle P, Hardy M, Morton S et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta‐analysis. JAMA, 2003; 289: 1537 – 1545.en_US
dc.identifier.citedreferenceDepartment of Health and Human Services. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; final rule. Fed Reg, 2004; 69: 6787 – 6854.en_US
dc.identifier.citedreferenceWhite L, Gardner S, Marx M, Wang P, Estes M. Pharmacokinetics and cardiovascular effects of ma‐huang ( Ephedra sinica ) in normotensive adults. J Clin Pharmacol, 1997; 37: 116 – 122.en_US
dc.identifier.citedreferencePalamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy, 2011; 99: 1 – 9. doi: 10.1016/j.healthpol.2010.07.007.en_US
dc.identifier.citedreferenceBailes J, Cantu R, Day A. The neurosurgeon in sport: awareness of the risks of heatstroke and dietary supplements. Neurosurgery, 2002; 51: 283 – 288. doi: 10.1227/01.NEU.0000020569.68133.12.en_US
dc.identifier.citedreferenceKernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med, 2000; 343: 1826 – 1832. doi: 10.1056/NEJM200012213432501.en_US
dc.identifier.citedreferencePadwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007; 369: 71 – 77. doi: 10.1016/S0140‐6736(07)60033‐6.en_US
dc.identifier.citedreferenceRucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta‐analysis. BMJ, 2007; 335: 1194 – 1199. doi: 10.1136/bmj.39385.413113.25.en_US
dc.identifier.citedreferencePadwal R, Li S, Lau D Long‐term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev, 2004; 3: CD004094.en_US
dc.identifier.citedreferenceTorgeson J, Hauptman J, Boldrin M, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 2004; 27: 155 – 161.en_US
dc.identifier.citedreferenceHaddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord, 2002; 26: 262 – 273. doi: 10.1038/sj.ijo.0801889.en_US
dc.identifier.citedreferenceCharakida M, Finer N. Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs, 2012; 12: 93 – 104. doi: 10.2165/11599000‐000000000‐00000.en_US
dc.identifier.citedreferenceKang JG, Park C‐Y. Anti‐obesity drugs: a review about their effects and safety. Diabetes Metab J, 2012; 36: 13 – 25. doi: 10.4093/dmj.2012.36.1.13.en_US
dc.identifier.citedreferenceMiller K. Serotonin 5‐HT2c receptor agonists: potential for the treatment of obesity. Mol Interv, 2005; 5: 282 – 291.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jcpt12177.pdf
Size:
539.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.